Carmela Ciardullo

Carmela Ciardullo

Auto-generated profile, based on publicly available information

Carmela Ciardullo

Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CCCarmela Ciardullo
Carmela Ciardullo
LTLuis Tobalina
Luis Tobalina
TCT. Hedley Carr
T. Hedley Carr
PSPhilip Szekeres
Philip Szekeres
SKSilvija Kraljevic
Silvija Kraljevic
GFGiulia Fabbri
Giulia Fabbri
Purpose: Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis despite initial treatment responses. This study evaluates ctDNA for monitoring disease and assessing the efficacy of first-line therapy in patients with extensive-stage SCLC (1L ES-SCLC). Experimental Design: In the TAZMAN trial, 31 patients with 1L ES-SCLC received standard treatment with durvalumab and etoposide plus carboplatin or cisplatin. We analyzed 228 plasma samples from 27 of 31 patients using a liquid biopsy approach to detect somatic mutations and copy-number aberrations, while also accounting for clonal hematopoiesis mutations. Results: Baseline ctDNA analysis detected somatic alterations in 96.3% of patients, primarily in genes like TP53 and RB1. ctDNA dynamics during early treatment showed significant reductions in variant allele frequency, confirming early but short-lived chemosensitivity. Reduction of ctDNA below the limit of detection of the assay during induction predicted patients with longer treatment duration, surpassing imaging in distinguishing these patients. ctDNA changes often anticipated disease relapse before conventional imaging, suggesting ctDNA as a more sensitive treatment efficacy marker. Conclusions: The study shows that early ctDNA dynamics can provide valuable insights into treatment efficacy and potential molecular relapse in 1L ES-SCLC. ctDNA can enhance treatment monitoring and potentially guide the discontinuation of ineffective therapies. Larger studies with extended next-generation sequencing panels are needed to fully understand the potential of ctDNA in SCLC management from diagnosis to treatment and recurrence surveillance.

4 September 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
RBRichard D. Baird
Richard D. Baird
BHBegoña Bermejo de Las Heras
Begoña Bermejo de Las Heras
MRManuel Ruiz-Borrego
Manuel Ruiz-Borrego
CVChristos Vaklavas
Christos Vaklavas
IMIrene Moreno
Irene Moreno
IVIvan Victoria
Ivan Victoria
Purpose: This trial investigated the safety and tolerability of camizestrant with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in women with estrogen receptor–positive, HER2− advanced breast cancer. Patients and Methods: SERENA-1 (NCT03616587) is a phase I, multipart, open-label study in women with refractory estrogen receptor–positive, HER2− advanced breast cancer. Patients received oral once-daily camizestrant 75 or 150 mg plus abemaciclib; camizestrant 75, 150, or 300 mg plus palbociclib; or camizestrant 75 mg plus ribociclib 400 or 600 mg. Safety/tolerability, pharmacokinetics, efficacy, and impact on estrogen receptor 1 mutation ctDNA were assessed. Results: By September 16, 2024 (data cutoff), 53 patients had received camizestrant plus abemaciclib, 78 camizestrant plus palbociclib, and 60 camizestrant plus ribociclib. Patients had a median of 2 (range, 0–7) prior regimens for advanced disease; 83% had received a prior CDK4/6i and 59% prior fulvestrant. The most common treatment-emergent adverse events for camizestrant 75 mg (phase III dose) plus each CDK4/6i were diarrhea [with abemaciclib (87.5%)] and neutropenia [with palbociclib (80%) and ribociclib (32.1% for 400 mg and 53.1% for 600 mg)]. The median camizestrant tmax was ∼4 hours postdose across combinations, with an estimated half-life of 9.5 to 17 hours. No clinically meaningful drug–drug interactions were evident. In this heavily pretreated population, CBR24 was 49.5% and the median progression-free survival was 7.4 months (95% confidence interval, 5.3–9.3), with antitumor activity across all combinations, including patients previously treated with CDK4/6i and/or fulvestrant, with or without estrogen receptor 1 mutation. Conclusions: Camizestrant is well tolerated, with antitumor activity in combination with CDK4/6i. These results support the evaluation of camizestrant 75 mg plus standard CDK4/6i doses in phase III trials.

21 January 2026 in ESMO Open
Verified
Journal Article
Open access
CVC. Vaklavas
C. Vaklavas
Mafalda OliveiraMafalda Oliveira
Mafalda Oliveira
AAA.C. Armstrong
A.C. Armstrong
IMI. Moreno
I. Moreno
CTC. Twelves
C. Twelves
RBR.D. Baird
R.D. Baird
Camizestrant, the next-generation oral selective estrogen receptor degrader and complete estrogen receptor (ER) antagonist, has previously demonstrated superiority over fulvestrant in patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Capivasertib is a selective AKT inhibitor recommended with fulvestrant for patients with PIK3CA/AKT1/PTEN-altered ER-positive, HER2-negative advanced breast cancer. Here, we report data from Parts I and J of SERENA-1 (NCT03616587), evaluating the safety, tolerability, pharmacokinetics and efficacy for the combination of camizestrant and capivasertib. SERENA-1 is a phase I, open-label, multi-part trial of camizestrant alone and in combination with other anticancer agents in women with ER-positive, HER2-negative advanced breast cancer. In parts I and J, participants received oral camizestrant 75 mg (once daily) in combination with oral capivasertib 400 mg (4 days on, 3 days off). Participants (n = 29) had a median of two previous lines of therapy in the advanced setting; 55.2% had received fulvestrant and 89.7% had received a cyclin-dependent kinase 4/6 inhibitor. Camizestrant in combination with capivasertib had a well-tolerated safety profile, with diarrhea (75.9%) and nausea (44.8%) being the most common adverse events. Median tmax was achieved ∼4 hours and ∼2 hours post dose for camizestrant and capivasertib, respectively. Clinical benefit at 24 weeks was seen in 51.7% of participants, and median progression-free survival was 8.3 months. In these pretreated participants, camizestrant 75 mg in combination with capivasertib 400 mg was well tolerated, with a side effect profile consistent with each drug as monotherapy, and showed encouraging evidence of clinical efficacy.

1 July 2018 in Cancer Research
Verified
Journal Article
Closed access
EWElaine Willmore
Elaine Willmore
YZYan Zhao
Yan Zhao
CCCarmela Ciardullo
Carmela Ciardullo
LWLaura Woodhouse
Laura Woodhouse
HTHuw D. Thomas
Huw D. Thomas
SWSteve Wedge
Steve Wedge
We investigated the cellular response to two MDM2-p53 antagonists (RG7388 and Cpd 1) in a panel of 19 tumor cell lines and in patient-derived chronic lymphocytic leukemia (CLL) cells. RG7388 (Idasanutlin) is an MDM2-p53 antagonist developed by Roche and Cpd1 a novel potent and selective MDM2-p53 antagonist developed as part of an ongoing Alliance between Newcastle University, Cancer Research UK and Astex Pharmaceuticals. RG7388 and Cpd1 potently inhibited the proliferation of many cell lines, with MDM2-amplified SJSA-1 osteosarcoma cells and cells from haematological malignancies being the most sensitive (e.g. GI50 values in the acute myeloid leukemia cell line MOLM13 were 33 + 16 nM for RG7388 and 8 + 1 nM for Cpd 1). We also examined induction of apoptosis by measuring caspase 3/7 activation (24 h treatment). SJSA-1 cells showed a 20-fold increase in caspase activation and Molm13 cells a 6-fold increase (measured at 300nM with RG7388). However, cell lines from solid tumours such as the colorectal carcinoma HCT116 or the hepatocellular carcinoma HepG2 did not show any induction of apoptosis, even at concentrations up to 1µM RG3788. In primary CLL cells, Cpd 1 reduced cell viability (48 h) with an average LC50 of 131 + 46 nM (n = 4), compared to 400 + 55 nM for RG7388 (n =23). We also quantified mRNA levels in 25 primary CLL samples and found that RG7388 induced a predominantly pro-apoptotic gene signature: following 6h treatment, 1µM RG7388 resulted in an average 8-fold induction of PUMA and 3.5-fold increase in BAX compared to a 1.6-fold induction of CDKN1A (p21). Our data confirm that targeting the MDM2-p53 interaction is an effective strategy to inhibit growth and viability of tumor cells, and that some cells, including those expressing high levels of MDM2 or those derived from hematological malignancies, display a striking apoptotic response. Citation Format: Elaine Willmore, Yan Zhao, Carmela Ciardullo, Laura Woodhouse, Huw D. Thomas, Maria Ahn, Lynsey Fazal, Martin E. Noble, Ian Hardcastle, Steven Howard, Gianni Chessari, John Lunec, Steve Wedge. The anti-proliferative and pro-apoptotic effect of MDM2-p53 antagonists evaluated in human tumor cells lines and chronic lymphocytic leukemia patient samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1870.

3 November 2025
Verified
Other
Open access
CCCarmela Ciardullo
Carmela Ciardullo
LTLuis Tobalina
Luis Tobalina
TCT. Hedley Carr
T. Hedley Carr
PSPhilip Szekeres
Philip Szekeres
SKSilvija Kraljevic
Silvija Kraljevic
GFGiulia Fabbri
Giulia Fabbri
Supplementary Figure 5 shows the RECIST and ctDNA longitudinal assessment in four representative patients.

3 November 2025
Verified
Other
Open access
CCCarmela Ciardullo
Carmela Ciardullo
LTLuis Tobalina
Luis Tobalina
TCT. Hedley Carr
T. Hedley Carr
PSPhilip Szekeres
Philip Szekeres
SKSilvija Kraljevic
Silvija Kraljevic
GFGiulia Fabbri
Giulia Fabbri
Supplementary Figure 2 shows a density histogram of n = 27 baseline plasma ctDNA samples with copy number (log2 ratio) indicated on the x-axis and counts/density on the y-axis.